NCT00636545View on ClinicalTrials.gov

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2010

Conditions

Solid Tumors

Interventions

DRUG

Oblimersen (Genasense)

Intravenous

DRUG

Oblimersen (Genasense)

Intravenous

Trial Locations (1)

78229

South Texas Accelerated Research Therapeutics, San Antonio

Sponsors

Lead Sponsor

Genta Incorporated

All Listed Sponsors

lead

Genta Incorporated

INDUSTRY

NCT00636545 - Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter